Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria

Abstract A single 300 mg dose of tafenoquine (an 8-aminoquinoline), in combination with a standard 3-day course of chloroquine, is approved in several countries for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged ≥ 16 years. Despite this, questions have arisen o...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Raman Sharma, Hema Sharma, Siôn Jones, Isabelle Borghini-Fuhrer, Gonzalo J. Domingo, Rachel A. Gibson, Katie Rolfe, Lionel Tan, Ioana Gabriela Fiţa, Chao Chen, Panayota Bird, Anup Pingle, Stephan Duparc
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-05-01
coleção:	Malaria Journal
Assuntos:	Plasmodium vivax malaria Radical cure Tafenoquine Benefit–risk
Acesso em linha:	https://doi.org/10.1186/s12936-024-04924-z
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!